RCT of mTORC1 inhibitor everolimus safety and effects on aging markers in older adults
This randomized controlled trial tested whether 24 weeks of mTORC1 inhibition via everolimus (0.5 mg daily or 5 mg weekly) could improve physiological and molecular hallmarks of aging. Participants aged 55-80 with insulin resistance or prediabetes received active treatment; a younger comparison group (ages 18-35) did not receive intervention.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 4, 2026 · Discovered: Sep 18, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 38 months
- Population
- Participants aged 55-80 years old who are insulin resistant or prediabetic (intervention group); Participants aged 18-35 (non-intervention control group)
- Primary outcome
- Safe improvement in physiological and molecular hallmarks of aging in humans
- Effect size
- —
- Significance
- Not reported
- Journal
- University of Wisconsin, Madison
- Published
- Sep 4, 2026
Sources
Primary source
- University of Wisconsin, Madison ↗Clinical trial
Source versions
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.